ARTICLE | Deals
Cytokinetics evaluating path forward for heart disease treatment after Amgen ends partnership
November 23, 2020 7:30 PM UTC
Cytokinetics is assessing whether to commercialize omecamtiv mecarbil on its own or to seek a new partner after Amgen returned the heart failure treatment’s rights, ending a 2006 deal.
President and CEO Robert Blum told a conference call Monday that the agreement’s termination came as a surprise to Cytokinetics Inc. (NASDAQ:CYTK), which had intended to discuss its next steps with Amgen Inc. (NASDAQ:AMGN) next quarter. “We had no indications prior to Friday that Amgen would choose to provide their termination notice” before those next steps took shape, he said...